S. Demattos

Evaluation of quaternized and neutral muscarinic receptor ligands in normal and DES-treated rat.

P. Sherman, G. Hingorani, G. K. Mulholland, 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonists

T. Heffner, H. Akunne, L. Wise, 1995, Peptides.

5,7-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H- pyrrolo[3,2-f]-1,2-benzisoxazol-6-one: a potent and centrally-selective inhibitor of acetylcholinesterase with an improved margin of safety.

A. Villalobos, A. Nagel, D. Liston, 1995, Journal of medicinal chemistry.

5,7‐Dihydro‐3‐(2‐(1‐(phenylmethyl)‐4‐piperidinyl)ethyl)‐6H‐pyrrolo(3,2‐ f)‐1,2‐benzisoxazol‐6‐one: A Potent and Centrally‐Selective Inhibitor of Acetylcholinesterase with an Improved Margin of Safety.

Andres D. Ramirez, W. White, A. Villalobos, 1995 .

Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers.

R. Anziano, G. Apseloff, N. Gerber, 2000, British journal of clinical pharmacology.

Characterization of the human dopamine D3 receptor expressed in transfected cell lines.

R. Todd, K. O’Malley, R. Mackenzie, 1994, European journal of pharmacology.

Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.

T. Pugsley, Y. Shih, S. Whetzel, 1992, Journal of Pharmacology and Experimental Therapeutics.

Agonist properties of a stable hexapeptide analog of neurotensin, N alpha MeArg-Lys-Pro-Trp-tLeu-Leu (NT1).

T. Heffner, H. Akunne, L. Wise, 1995, Biochemical pharmacology.